Clinical Trial Update: Study of the Efficacy and Safety of Lonidamine for the Treatment of Symptomatic Benign Prostatic Hyperplasia [Phase 2]

View source ↗

Summary

Phase 2 study evaluating lonidamine for symptomatic benign prostatic hyperplasia was terminated. The update does not include efficacy or safety results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Benign Prostatic Hyperplasia

Drugs mentioned

• Lonidamine (lonidamine)

Snippet

Sponsor: Threshold Pharmaceuticals | Conditions: Benign Prostatic Hyperplasia | Phase 2 | Status: TERMINATED